(Q45267389)

English

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors

scientific article published on 15 February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors (English)

1 reference

Europe PubMed Central

11 December 2017

0 references

1 reference

based on heuristic

inferred from title

Gilles Peytavin

3

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

11 December 2017

author name string

Michel Duong

1

1 reference

Europe PubMed Central

11 December 2017

Marielle Buisson

2

1 reference

Europe PubMed Central

11 December 2017

Evelyne Kohli

4

1 reference

Europe PubMed Central

11 December 2017

Lionel Piroth

5

1 reference

Europe PubMed Central

11 December 2017

Benoit Martha

6

1 reference

Europe PubMed Central

11 December 2017

Michèle Grappin

7

1 reference

Europe PubMed Central

11 December 2017

Pascal Chavanet

8

1 reference

Europe PubMed Central

11 December 2017

Henri Portier

9

1 reference

Europe PubMed Central

11 December 2017

language of work or name

0 references

publication date

15 February 2005

1 reference

Europe PubMed Central

11 December 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

11 December 2017

39

1 reference

Europe PubMed Central

11 December 2017

4

1 reference

Europe PubMed Central

11 December 2017

603-609

1 reference

Europe PubMed Central

11 December 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Defining the toxicity profile of nevirapine and other antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Liver toxicity caused by nevirapine

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Identifiers

10.1345/APH.1E563

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45267389&oldid=2072215130"